Marshall Wace LLP bought a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund bought 45,947 shares of the biopharmaceutical company’s stock, valued at approximately $740,000.
A number of other institutional investors have also made changes to their positions in HALO. Bank of Montreal Can grew its holdings in shares of Halozyme Therapeutics by 80.4% in the 4th quarter. Bank of Montreal Can now owns 2,011 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 896 shares during the last quarter. Sageworth Trust Co grew its holdings in shares of Halozyme Therapeutics by 4,200.0% during the first quarter. Sageworth Trust Co now owns 2,150 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 2,100 shares in the last quarter. Amundi Pioneer Asset Management Inc. purchased a new position in Halozyme Therapeutics in the fourth quarter valued at about $140,000. Pathlight Investors LLC purchased a new position in Halozyme Therapeutics in the fourth quarter valued at about $151,000. Finally, Paloma Partners Management Co purchased a new position in Halozyme Therapeutics in the fourth quarter valued at about $150,000. 82.07% of the stock is currently owned by hedge funds and other institutional investors.
A number of research analysts have commented on HALO shares. BidaskClub upgraded Westport Fuel Systems from a “hold” rating to a “buy” rating in a research note on Friday, July 12th. Cantor Fitzgerald assumed coverage on Veru in a research report on Monday, July 1st. They issued an “overweight” rating and a $6.00 price target for the company. Zacks Investment Research raised Golub Capital BDC from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a research report on Tuesday. Finally, ValuEngine raised Zogenix from a “buy” rating to a “strong-buy” rating in a research report on Thursday, June 27th. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $21.00.
Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported $0.01 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.01. The firm had revenue of $56.95 million for the quarter, compared to analyst estimates of $67.80 million. Halozyme Therapeutics had a negative return on equity of 20.36% and a negative net margin of 28.70%. The business’s quarterly revenue was up 84.3% compared to the same quarter last year. During the same period last year, the company earned ($0.19) EPS. On average, equities analysts forecast that Halozyme Therapeutics, Inc. will post -0.42 earnings per share for the current fiscal year.
Halozyme Therapeutics Profile
Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.